• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

10.00 -0.22 (-2.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
7 Bull Flag Setups Found With the ChartMill Stock Screener ↗
April 28, 2026
Via Chartmill
News headline image
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 ↗
April 12, 2026
Focused on infectious disease therapies, this biotech firm reported a notable insider sale amid a year of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick ↗
April 07, 2026
Via Chartmill
Unusual volume stocks are being observed in Monday's session. ↗
March 02, 2026
Via Chartmill
News headline image
Vir Biotechnology to Participate in Upcoming Investor Conferences
February 26, 2026
From Vir Biotechnology, Inc.
Via Business Wire
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
February 26, 2026
Via Chartmill
Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗
February 23, 2026
Via Chartmill
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
November 09, 2025
Via Stocktwits
News headline image
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
February 25, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Proposed Public Offering of Common Stock
February 24, 2026
From Vir Biotechnology, Inc.
Via Business Wire
Tuesday's session: top gainers and losers ↗
February 24, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
November 05, 2025
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
February 24, 2026
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
February 24, 2026
Via Chartmill
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
February 24, 2026
Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
Via Stocktwits
News headline image
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗
February 23, 2026
The company said its current resources are expected to fund operations into the second quarter of 2028. 
Via Stocktwits
Topics Earnings
News headline image
Vir Biotechnology (VIR) Earnings Call Transcript ↗
February 23, 2026
Vir Biotechnology (VIR) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
February 23, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
February 09, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
January 12, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
December 16, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
December 07, 2025
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
November 19, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
November 09, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
November 07, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 05, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
November 03, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
October 22, 2025
From Vir Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap